You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Bulk Pharmaceutical API Sources for triamterene


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for triamterene

Vendor Vendor Homepage Vendor Sku API Url
Sigma-Aldrich ⤷  Get Started Free T4143_SIGMA ⤷  Get Started Free
Vitas-M Laboratory ⤷  Get Started Free STK300348 ⤷  Get Started Free
TCI (Tokyo Chemical Industry) ⤷  Get Started Free T1288 ⤷  Get Started Free
Molport ⤷  Get Started Free MolPort-001-641-070 ⤷  Get Started Free
Hangzhou APIChem Technology ⤷  Get Started Free AC-14066 ⤷  Get Started Free
AKos Consulting & Solutions ⤷  Get Started Free AKOS003790819 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for: Triamterene

Last updated: July 28, 2025

Introduction

Triamterene is a potent potassium-sparing diuretic primarily prescribed for conditions such as edema and hypertension. As an essential API in pharmaceutical formulations, ensuring high-quality, reliable sourcing is vital for manufacturers, regulatory compliance, and patient safety. This report illuminates the global landscape of bulk API suppliers for triamterene, with detailed insights into key manufacturers, sourcing trends, and considerations for procurement.

Global Manufacturing Landscape of Triamterene API

The triamterene API market is concentrated across North America, Asia, and Europe, with manufacturing hubs in India, China, and the United States. India and China dominate as primary API producers owing to their robust pharmaceutical manufacturing infrastructure and cost competitiveness. The United States, while hosting high-quality API producers, often relies on imports for triamterene to meet domestic demand.

Key API Suppliers

India: India remains a leading source of triamterene API, owing to its well-established pharmaceutical industry and exemption from certain stringent international regulations. Major players include:

  • Glenmark Pharmaceuticals: A reputable Indian pharmaceutical company with established API manufacturing capabilities, including triamterene, verified by certifications such as WHO-GMP.
  • Aurobindo Pharma: Offers a comprehensive portfolio of bulk APIs, including triamterene, with global export presence.
  • Sun Pharmaceutical Industries: Facilities capable of producing high-quality triamterene APIs, serving both domestic and export markets.

China: China's pharmaceutical API sector is characterized by high-volume capacity and competitive pricing. Notable suppliers include:

  • Hepalink Pharmaceutical Group: Specializes in active pharmaceutical ingredients, with dedicated facilities for diuretic APIs such as triamterene.
  • Jiangsu Hualan Bio-Medical Engineering: Provides bulk APIs with recent WHO-GMP certifications for compliance.
  • Zhejiang Hancort Pharmaceutical Co., Ltd.: Known for producing diverse diuretic APIs including triamterene, catering to international markets.

United States: The U.S. hosts a limited number of API manufacturers primarily serving high-standard markets:

  • Induchem (a division of Bachem): Offers high-quality, FDA-compliant triamterene API manufacturing services, usually tailored for branded and generic pharmaceutical firms.
  • Amneal Pharmaceuticals: Has API manufacturing capabilities with robust regulatory adherence, serving both domestic and global markets.

Regulatory and Quality Considerations

Procurement from API suppliers requires stringent evaluation of quality standards, certifications, and regulatory track records. Suppliers with WHO-GMP, FDA, or EU-GMP certifications are preferred for compliance with international quality standards. Additionally, suppliers should demonstrate consistent batch-to-batch purity, potency, and stability, backed by validated analytical methods.

Sourcing Trends and Strategic Considerations

  • Cost Flexibility: Chinese and Indian suppliers provide cost-effective options, but manufacturers must assess long-term regulatory, supply stability, and quality risks.
  • Regulatory Compliance: U.S. and European manufacturers impose stricter regulatory standards, suitable for markets requiring high compliance.
  • Supply Chain Security: Increasing demand for API traceability and transparency has led to the adoption of integrated supply chain management, including detailed audit reports and batch certifications.
  • Technological Innovation: Manufacturers investing in green synthesis methods and high-purity production techniques are gaining preference due to regulatory emphasis on environmental and safety standards.

Challenges in API Sourcing

  • Quality Variability: Due to diverse manufacturing practices, quality inconsistencies may arise, necessitating rigorous auditing.
  • Regulatory Barriers: Divergent regional regulations can delay approvals and impact supply chains.
  • Supply Disruptions: Political, logistical, or pandemic-related disruptions pose risks, emphasizing the importance of diversified sourcing strategies.

Conclusion

The global triamterene API sourcing landscape is complex, shaped by manufacturing capacity, regulatory compatibility, and quality assurance. Leading suppliers from India and China offer cost-effective solutions with extensive production capabilities, while U.S. suppliers prioritize quality and regulatory compliance. Strategic procurement involves balancing cost, quality, regulatory alignment, and supply chain resilience.

Key Takeaways

  • Indian and Chinese manufacturers present the most significant global supply options for triamterene API, often providing cost advantages.
  • Suppliers with internationally recognized GMP certifications are imperative to meet regulatory standards in developed markets.
  • Diversification of API sources mitigates supply risks associated with geopolitical, logistical, or pandemic disruptions.
  • Continuous supplier qualification, including audits and batch record evaluation, is essential for maintaining quality assurance.
  • Investment in supply chain transparency and traceability remains critical in today’s regulated pharmaceutical environment.

FAQs

  1. What are the primary factors to consider when sourcing triamterene API?
    Quality certifications, purity standards, production capacity, supply reliability, and regulatory compliance are crucial.

  2. Are Chinese and Indian API suppliers compliant with international standards?
    Many leading suppliers hold certifications like WHO-GMP and ISO, but due diligence and audits are necessary before engagement.

  3. How does regulatory compliance influence API sourcing decisions?
    It dictates market access, especially in the U.S. and Europe, where stringent approval processes necessitate high-quality, compliant API sources.

  4. What risks are associated with sourcing from Asian manufacturers?
    Potential quality variability, regulatory hurdles, and geopolitical issues require thorough supplier qualification and risk mitigation strategies.

  5. Can U.S. API manufacturers supply triamterene in large quantities?
    While capable, U.S. API manufacturing tends to focus on high-end, compliant production for niche markets due to higher costs and capacity constraints.

References

[1] IQVIA Institute. (2022). The Future of Pharmacovigilance and API Supply Chains.
[2] WHO. (2021). WHO Global Benchmarking Tool for National Regulatory Authorities of Medicines.
[3] European Medicines Agency. (2022). Guideline on Active Substance Quality.
[4] U.S. Food and Drug Administration. (2023). Current Good Manufacturing Practice (CGMP) Regulations for Finished Pharmaceuticals.
[5] Clark, K. & Patel, R. (2022). "Global API Market Trends and Sourcing Strategies," Journal of Pharmaceutical Manufacturing.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.